Targanta Therapeutics Inc.
Biotech Specialty Pharma
7170 Frederick Banting, 2nd Floor
St. Laurent, QC H4S 2A1 Canada
phone: (514) 332-1008
fax: (514) 332-6033
Symbol Private
Founded 0
Employees
www.targanta.com
Research Sector Biotech Specialty Pharma
Summary Description
Antibacterial agents.
Management
Mark Leuchtenberger, President and Chief Executive Officer; George A. Eldridge, Senior Vice President Finance and Administration and Chief Financial Officer; Pierre E. G. Etienne, M.D., Chief Development Officer; Tom Parr, Ph.D., Chief Scientific Officer
Keywords
antibacterial, oritavancin, semisynthetic, glycopeptide, Gram-positive, infection

Comment | Printable Version | May 17, 2007
If you work for Targanta Therapeutics Inc. and want to update this profile, click here


Description
Targanta Therapeutics, Inc. is focused on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market.
Products / Services
Targanta's latest-stage antibacterial drug, oritavancin, is a semisynthetic glycopeptide with potent bactericidal activity against nearly all clinically relevant, difficult-to-treat Gram-positive infections.


2008-11-11-337